Alkermes (ALKS)
(Delayed Data from NSDQ)
$27.37 USD
+0.78 (2.93%)
Updated Oct 10, 2024 04:00 PM ET
After-Market: $27.36 -0.01 (-0.04%) 6:26 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.37 USD
+0.78 (2.93%)
Updated Oct 10, 2024 04:00 PM ET
After-Market: $27.36 -0.01 (-0.04%) 6:26 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
CVS Health (CVS) Q1 Earnings Top Estimates, '22 EPS View Up
by Zacks Equity Research
CVS Health (CVS) reports better-than-expected results for Q1, with robust segmental performance driving the top line.
Masimo's (MASI) Q1 Earnings Surpass Estimates, FY22 View Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments drive its Q1 sales.
Cerner (CERN) Q1 Earnings in Line, Revenues Lag Estimates
by Zacks Equity Research
Cerner's (CERN) first-quarter results benefit from gains across four of its business units.
PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results benefit from a solid performance at Discover & Analytics Solutions business.
IDEXX (IDXX) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Strong sales at the CAG and Water businesses drove IDEXX's (IDXX) first-quarter 2022 revenues.
AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter results benefit from segmental growth.
Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, FY22 View Up
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions recorded year-over-year sales growth at CER.
Catalent (CTLT) Q3 Earnings Beat Estimates, FY22 View Up
by Zacks Equity Research
Catalent's (CTLT) robust performance across most of its segments drives its third-quarter fiscal 2022 top line.
Henry Schein (HSIC) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Robust performances by all three operating segments drove Henry Schein's (HSIC) first-quarter 2022 revenues.
Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Robust sales performance across Omnicell's (OMCL) operating segments has contributed to the first-quarter top line.
Integer Holdings (ITGR) Q1 Earnings, Revenues Lag Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect robust segmental performances besides strength in the majority of the product lines.
Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.
5 Top Stocks Likely to Beat Earnings Estimates
by Sanghamitra Saha
These top-ranked stocks (ALKS, DRVN, TSLA, CIB, TFII) are likely to beat on bottom line in their next releases.
Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View
by Zacks Equity Research
Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.
Accuray (ARAY) Q3 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
Despite strong product demand, Accuray (ARAY) reports an overall soft Q3 performance.
Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across its segments.
DexCom (DXCM) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Despite a decline in bottom line, DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth and solid new customer additions.
Alkermes (ALKS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Alkermes (ALKS) rides high on both earnings and sales beating estimates in the first quarter of 2022.
Alkermes (ALKS) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 1,100% and 6.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More
by Kanishka Das
Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.
Teva's (TEVA) Schizophrenia Drug Gets CRL From the FDA
by Zacks Equity Research
Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone to treat schizophrenia faces rejection from the FDA.
Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 6.4% Jump Turn into More Strength?
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Alkermes (ALKS) Up 2.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) rides high on both earnings and sales beating estimates in the fourth quarter of 2021.
Alkermes (ALKS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 76.92% and 1.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?